Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim and Darbepoetin Alfa in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer
NCT00146562Phase 2Completed
- Sponsor
- Harold J. Burstein
- Start
- Jul 2003
- Primary completion
- May 2007
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim and darbepoetin alfa in neutropenia and anemia, sponsored by Harold J. Burstein. Primary endpoint: Rate of febrile neutropenia at 2 years. Started Jul 2003; status: completed.
02
Drugs
pegfilgrastimdarbepoetin alfa
03
Conditions
neutropeniaanemia
Beyond the preview
Go deeper on NCT00146562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146562.